SCHEMBL2195443

SCHEMBL2195443

O=[N+]([O-])c1ccc(O)nc1Nc1ccccc1SC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 1/20 0.39
L3MBTL1 Q9Y468 4/20 0.38
ALDH1A1 P00352 4/20 0.38
PKM P14618 2/20 0.38
HTT P42858 2/20 0.38
HPGD P15428 1/20 0.38
FGFR4 P22455 1/20 0.38
PTK2 Q05397 1/20 0.37
AKR1B1 P15121 1/20 0.37
AKR1C4 P17516 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
AKR1C1 Q04828 1/20 0.37
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
GAA P10253 4/20 0.36
MAPK1 P28482 4/20 0.36
MAPT P10636 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
GSK3B P49841 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191805 0.85 KMT2A (0.46) L3MBTL1ALDH1A1PKMMEN1KMT2A
SCHEMBL2194289 0.81 ALDH1A1 (0.46) L3MBTL1ALDH1A1PKMFGFR4PTK2
SCHEMBL2191393 0.80 CXCR2 (0.44) L3MBTL1ALDH1A1PKMMEN1KMT2A
SCHEMBL2197093 0.80 MEN1 (0.46) L3MBTL1ALDH1A1PKMHTTMEN1
SCHEMBL2192393 0.79 HTT (0.39) L3MBTL1ALDH1A1PKMHTTHPGD
SCHEMBL2194871 0.79 L3MBTL1 (0.46) PRKCQL3MBTL1ALDH1A1PKMAKR1B1
SCHEMBL2192755 0.77 KMT2A (0.51) L3MBTL1ALDH1A1PKMHTTHPGD
SCHEMBL2196630 0.77 MAPK1 (0.55) L3MBTL1ALDH1A1PKMHTTHPGD
SCHEMBL2194211 0.75 MEN1 (0.37) L3MBTL1ALDH1A1PKMMEN1KMT2A
SCHEMBL2194787 0.73 IGF1R (0.38) L3MBTL1ALDH1A1PKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 PRKCQ 2106/4885L3MBTL1 4688/4885ALDH1A1 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.